Wolverine Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Wolverine Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-115,812	Closed	-$3.99M	–	2104
2020 Q3	$3.99M	Buy	+115,812	New	+$2.47M	0.04%	264

Wolverine Asset Management's AIMT Position: Q4 2020 in Review

Wolverine Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 115,812 shares — an estimated $3.99M sold.

Wolverine Asset Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $3.99M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Wolverine Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Wolverine Asset Management sold 115,812 Aimmune Therapeutics shares in Q4 2020, an estimated $3.99M.
Wolverine Asset Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Wolverine Asset Management's Aimmune Therapeutics position peaked at $3.99M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Wolverine Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.